Journal of drugs in dermatology : JDD · 2026
Eyebrow Madarosis: An Updated Review of the Etiology and Management, Part II- Scarring Disorders.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nelson Janaya, Friedman Adam
Аннотация
BACKGROUND: Eyebrows play an essential role in facial symmetry, communication, and aesthetic identity. Scarring eyebrow alopecia results from inflammatory, autoimmune, infectious, genetic, traumatic, and iatrogenic processes that irreversibly damage follicular stem cells and limit regrowth potential. Despite its clinical and psychosocial impact, evidence-based guidance for diagnosis and management remains limited.
METHODS: A comprehensive PubMed search (1960–2025) was performed using terms related to "eyebrow alopecia," "eyebrow madarosis," and etiology-specific conditions. English-language original studies evaluating eyebrow involvement and reporting diagnostic or therapeutic outcomes were included. Review articles without original patient data and studies limited to scalp alopecia were excluded.
RESULTS: Scarring eyebrow alopecia included autoimmune conditions such as discoid lupus erythematosus and localized scleroderma; infectious etiologies such as lepromatous leprosy; genetic disorders including keratosis follicularis spinulosa decalvans; and inflammatory dermatoses such as ulerythema ophryogenes. Additional causes included radiation therapy, trauma, and hematologic malignancies. Reported treatments included corticosteroids, calcineurin inhibitors, antimalarials, methotrexate, mycophenolate, retinoids, JAK inhibitors, phototherapy, and reconstructive approaches. Emerging therapies, including biologics and regenerative techniques, have shown limited but evolving benefit.
CONCLUSION: Scarring eyebrow madarosis involves diverse irreversible etiologies. Early diagnosis and etiology-directed treatment are essential to limit progression, highlighting the need for standardized management algorithms and eyebrow-specific outcome measures.  .
METHODS: A comprehensive PubMed search (1960–2025) was performed using terms related to "eyebrow alopecia," "eyebrow madarosis," and etiology-specific conditions. English-language original studies evaluating eyebrow involvement and reporting diagnostic or therapeutic outcomes were included. Review articles without original patient data and studies limited to scalp alopecia were excluded.
RESULTS: Scarring eyebrow alopecia included autoimmune conditions such as discoid lupus erythematosus and localized scleroderma; infectious etiologies such as lepromatous leprosy; genetic disorders including keratosis follicularis spinulosa decalvans; and inflammatory dermatoses such as ulerythema ophryogenes. Additional causes included radiation therapy, trauma, and hematologic malignancies. Reported treatments included corticosteroids, calcineurin inhibitors, antimalarials, methotrexate, mycophenolate, retinoids, JAK inhibitors, phototherapy, and reconstructive approaches. Emerging therapies, including biologics and regenerative techniques, have shown limited but evolving benefit.
CONCLUSION: Scarring eyebrow madarosis involves diverse irreversible etiologies. Early diagnosis and etiology-directed treatment are essential to limit progression, highlighting the need for standardized management algorithms and eyebrow-specific outcome measures.  .